Barclays
VNDA icon

Barclays’s Vanda Pharmaceuticals VNDA Stock Holding History

Barclays’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-600
Closed -$10K – 7319
2018
Q1 		$10K Buy
+600
New +$10K ﹤0.01% 6663
2017
Q2 		– Sell
-600
Closed -$8K – 6965
2017
Q1 		$8K Sell
600
-8,800
-94% -$125K ﹤0.01% 6149
2016
Q4 		$150K Buy
9,400
+7,300
+348% +$117K ﹤0.01% 4444
2016
Q3 		$35K Buy
2,100
+200
+11% +$2.69K ﹤0.01% 5191
2016
Q2 		$21K Hold
1,900
– – ﹤0.01% 5254
2016
Q1 		$15K Sell
1,900
-24,700
-93% -$203K ﹤0.01% 5341
2015
Q4 		$239K Buy
26,600
+3,400
+15% +$33.9K ﹤0.01% 3766
2015
Q3 		$255K Sell
23,200
-1,700
-7% -$20.8K ﹤0.01% 3957
2015
Q2 		$299K Buy
24,900
+300
+1% +$3.23K ﹤0.01% 3875
2015
Q1 		$221K Sell
24,600
-507,100
-95% -$5.73M ﹤0.01% 4273
2014
Q4 		$7.44M Buy
531,700
+527,200
+11,716% +$6.24M 0.01% 1387
2014
Q3 		$45K Sell
4,500
-13,900
-76% -$182K ﹤0.01% 5965
2014
Q2 		$294K Buy
18,400
+1,600
+10% +$21.3K ﹤0.01% 4458
2014
Q1 		$269K Sell
16,800
-141,300
-89% -$2.01M ﹤0.01% 4515
2013
Q4 		$1.9M Buy
158,100
+25,900
+20% +$260K ﹤0.01% 2729
2013
Q3 		$1.32M Buy
132,200
+126,900
+2,394% +$1.36M ﹤0.01% 3051
2013
Q2 		$43K Buy
+5,300
New +$35.7K ﹤0.01% 6408

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's VNDA Position: Q2 2026 in Review

Barclays increased its Vanda Pharmaceuticals (VNDA) stake by 1% in Q2 2026, buying an estimated $5.49K and bringing the position to 81,650 shares worth $500K. The position accounts for ﹤0.01% of the portfolio, ranked #3232.

Barclays first reported a position in VNDA in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.94M in Q4 2013. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Barclays held 81,650 shares of Vanda Pharmaceuticals worth $500K as of Q2 2026.
  • Barclays bought 841 Vanda Pharmaceuticals shares in Q2 2026, an estimated $5.49K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3232 holding.
  • Barclays first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Vanda Pharmaceuticals position peaked at $3.94M in Q4 2013.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.